These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 16382000

  • 1. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N, Triptorelin 3-month CPP Study Group.
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F.
    J Pediatr Endocrinol Metab; 2016 Nov 01; 29(11):1241-1248. PubMed ID: 26887034
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH.
    J Korean Med Sci; 2021 Aug 30; 36(34):e219. PubMed ID: 34463062
    [Abstract] [Full Text] [Related]

  • 4. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
    Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, Lucas C, Chaussain JL.
    J Clin Endocrinol Metab; 2002 Sep 30; 87(9):4111-6. PubMed ID: 12213857
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, Bravo E, Cassorla F.
    J Pediatr Endocrinol Metab; 2006 Aug 30; 19(8):963-70. PubMed ID: 16995580
    [Abstract] [Full Text] [Related]

  • 7. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M, Di Maio S, Gasparini N, Mariano A, Macchia V, Tenore A.
    Horm Res; 1998 Aug 30; 50(4):205-11. PubMed ID: 9838241
    [Abstract] [Full Text] [Related]

  • 8. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E, Kim S, Jung HL, Shim JY, Shim JW, Kim DS, Kwak JH, Kim ES, Yang A.
    Front Endocrinol (Lausanne); 2023 Aug 30; 14():1134977. PubMed ID: 36875449
    [Abstract] [Full Text] [Related]

  • 9. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y.
    J Clin Endocrinol Metab; 1986 Apr 30; 62(4):670-7. PubMed ID: 2936759
    [Abstract] [Full Text] [Related]

  • 10. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct 30; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 11. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation
.
    Durand A, Tauber M, Patel B, Dutailly P.
    Horm Res Paediatr; 2017 Oct 30; 87(4):224-232. PubMed ID: 28334719
    [Abstract] [Full Text] [Related]

  • 12. Triptorelin depot stimulation test for central precocious puberty.
    Strich D, Kvatinsky N, Hirsch HJ, Gillis D.
    J Pediatr Endocrinol Metab; 2013 Oct 30; 26(7-8):631-4. PubMed ID: 23425599
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K.
    J Clin Endocrinol Metab; 2012 May 30; 97(5):1572-80. PubMed ID: 22344198
    [Abstract] [Full Text] [Related]

  • 14. Central precocious puberty: treatment with triptorelin 11.25 mg.
    Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, Einaudi S, Cappa M, Russo G, Bertelloni S.
    ScientificWorldJournal; 2012 May 30; 2012():583751. PubMed ID: 22645436
    [Abstract] [Full Text] [Related]

  • 15. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
    Bertelloni S, Mucaria C, Baroncelli GI, Peroni D.
    Expert Rev Clin Pharmacol; 2018 Jul 30; 11(7):659-667. PubMed ID: 29957076
    [Abstract] [Full Text] [Related]

  • 16. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
    Wide L, Albertsson-Wikland K, Phillips DJ.
    J Clin Endocrinol Metab; 1996 Jan 30; 81(1):216-21. PubMed ID: 8550754
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D, Blumberg J, Liyanage N, Jacqz-Aigrain E, Lahlou N, Carel JC, Co-Investigators.
    Horm Res Paediatr; 2016 Jan 30; 86(3):188-195. PubMed ID: 27603324
    [Abstract] [Full Text] [Related]

  • 19. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.
    Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, Price DA, Clayton PE.
    Clin Endocrinol (Oxf); 2002 Aug 30; 57(2):223-30. PubMed ID: 12153601
    [Abstract] [Full Text] [Related]

  • 20. Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty.
    Freire AV, Gryngarten MG, Ballerini MG, Arcari AJ, Escobar ME, Bergadá I, Ropelato MG.
    Horm Res Paediatr; 2016 Aug 30; 85(1):58-64. PubMed ID: 26675317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.